NEW YORK – Trovagene is exploring the activity of its PLK1 inhibitor onvansertib in three biomarker-defined cancer indications and, based on promising activity, is hoping to advance the drug into later-stage trials soon.
NEW YORK – Trovagene is exploring the activity of its PLK1 inhibitor onvansertib in three biomarker-defined cancer indications and, based on promising activity, is hoping to advance the drug into later-stage trials soon.
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.